Bluejay Diagnostics Reports First Quarter 2023 Financial Results

May 10, 2023  | 

ACTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today announced financial results for the quarter ended March 31, 2023.

“Our journey continues towards realizing Bluejay’s vision of improving patient outcomes by addressing time-sensitive, life-saving needs in critical care settings,” said Neil Dey, CEO of Bluejay Diagnostics. “Symphony’s potential to be a rapid near-patient testing platform providing laboratory quality results has already been affirmed by IL-6 data from our comprehensive clinical studies. More recently, all resources and efforts at Bluejay have been focused on aligning our expanded clinical study with FDA feedback to optimize the pathway to regulatory approval. We look forward to providing an update on our Symphony IL-6 clinical program during this quarter.”

Financial Results for the Three Months Ended March 31, 2023:

Cash and cash equivalents. Cash and cash equivalents on March 31, 2023 were $6.8 million, as compared to $10.1 million on December 31, 2022. The Company will limit its cash burn during the FDA submission process and continue to closely monitor the management of its liquidity.

Research and development expense. Research and development expenses for the three months ended March 31, 2023 was approximately $1.4 million as compared to approximately $695,000 for the same period in 2022. The increase in research and development expenses was primarily due to an increase in personnel costs and clinical trials expenses. We expect future research and development expenses to be focused on costs specifically associated with our clinical trial program supporting our regulatory strategy and any necessary manufacturing improvements.

General and administrative expense. General and administrative expenses for the three months ended March 31, 2023 was approximately $1.2 million as compared to approximately $1.3 million for the comparable period in 2022. The minor decrease in general and administrative expenses is due to continued efforts to preserve capital by limiting our investment in infrastructure commensurate with our commercialization timeline. We expect to monitor and continue to pare our general and administrative spend, as necessary, to optimize operational alignment.

Sales and marketing expense. Sales and marketing expenses for the three months ended March 31, 2023 was approximately $148,000 as compared to approximately $54,000 for the comparable period in 2022. We expect minimal sales and marketing efforts during 2023, appropriately corresponding our spend with bringing Symphony to market.

Net loss/Net loss per share. The net loss was $2.5 million, or $0.12 per share for the three months ended March 31, 2023, compared to $2.0 million, or $0.10 per share, for the comparable period in 2022.

About the SymphonyTM System:
Bluejay’s Symphony System (the “Symphony System”) is designed to address the need for simple, reliable, rapid, near-patient testing by providing quantitative measurements of specific biomarkers to determine the need for additional patient care and monitoring. The user-friendly Symphony System will not require any sample preparation or dedicated staff and was shown in published clinical studies to deliver results in approximately 20 minutes.

The Symphony IL-6 Test is a development stage product candidate for investigational use only. It is limited by United States law to investigational use.

About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis triage, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at

Forward-Looking Statements:

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements in this press release include, without limitation, the expected nature and timing of the Company’s planned FDA submission and related plans for clinical study expansion, whether the Company’s cash position will be sufficient to fund operations needed to achieve regulatory approval and initial commercialization of the Symphony IL-6 Test, and whether such regulatory approval will actually occur. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest”, “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events.

Investor Contact:
Alexandra Schuman
LifeSci Advisors
t: 646-876-3647

Bluejay Diagnostics, Inc.
Condensed Consolidated Balance Sheets

  March 31, 2023  December 31, 2022 
Current assets:      
Cash and cash equivalents $6,781,911  $10,114,990 
Prepaid expenses and other current assets  2,120,012   1,673,480 
Total current assets  8,901,923   11,788,470 
Property and equipment, net  1,519,722   1,232,070 
Operating lease right-of-use assets  433,361   465,514 
Other non-current assets  33,443   35,211 
Total assets $10,888,449  $13,521,265 
Current liabilities:        
Accounts payable $388,045  $635,818 
Operating lease liability, current  168,709   168,706 
Accrued expenses and other current liabilities  863,397   835,730 
Total current liabilities  1,420,151   1,640,254 
Operating lease liability, non-current  289,910   323,915 
Other non-current liabilities  14,970   15,823 
Total liabilities  1,725,031   1,979,992 
Commitments and Contingencies (See Note 13)        
Stockholders’ equity:        
Common stock, $0.0001 par value; 100,000,000 shares authorized; 20,459,057 and 20,215,288 shares issued and outstanding at March 31, 2023 and 2022, respectively  2,046   2,022 
Additional paid-in capital  28,698,317   28,536,353 
Accumulated deficit  (19,536,945)  (16,997,102)
Total stockholders’ equity  9,163,418   11,541,273 
Total liabilities and stockholders’ equity $10,888,449  $13,521,265 

Bluejay Diagnostics, Inc.
Condensed Consolidated Statements of Operations

  Three Months Ended
March 31,
  2023  2022 
Operating expenses:        
Research and development  1,354,549   694,757 
General and administrative  1,176,977   1,319,819 
Sales and marketing  148,046   53,685 
Total operating expenses  2,679,572   2,068,261 
Operating loss  (2,679,572)  (2,068,261)
Other income:        
Other income, net  139,729   54,858 
Total other income  (139,729)  (54,858)
Net loss $(2,539,843) $(2,013,403)
Net loss per share - Basic and diluted $(0.12) $(0.10)
Weighted average common shares outstanding:        
Basic and diluted  20,375,092   20,142,300